Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Merck Says It Failed to Win U.S. Approval for Two Treatments

Nov. 9 (Bloomberg) -- Merck & Co. failed to win U.S. approval of an oral contraceptive already sold in Europe and a glaucoma treatment on the market in nine countries.

The U.S. Food and Drug Administration sent “complete response letters” earlier this month on the contraceptive NOMAC/E2, available in Europe under the name Zoely, and on tafluprost, sold abroad as Saflutan, according to a regulatory filing by Merck, the second-biggest U.S. drugmaker.

“The company plans to have further discussions with the FDA,” said Ronald Rogers, a spokesman for Whitehouse Station, New Jersey-based Merck, in a phone interview. “We are not getting into any of the specifics of what was in the letter.”

Merck plans to highlight the company’s research at a meeting of analysts tomorrow. The drugmaker is attempting to come up with new medicines to replace revenue that will be lost when its best-selling product, the asthma drug Singulair, faces generic competition next year.

Rogers said that both Zoely and Saflutan were “smaller products” and that the company doesn’t break out individual sales figures for them. Merck licensed rights to tafluprost in markets including the U.S. from Santen Pharmaceutical Co., a Japanese maker of eye drugs, in 2009.

To contact the reporter on this story: Robert Langreth in New York at rlangreth@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.